NasdaqGS:IBRXBiotechs
Is It Too Late To Consider ImmunityBio (IBRX) After Its 261% Year To Date Surge?
Wondering if ImmunityBio at around US$7.30 is still priced for opportunity or already reflecting the story most investors see? This article is built to help you frame that question clearly.
The stock has delivered a 261.4% return year to date and 162.6% over the past year. However, the last 30 days show a 13.0% decline and the last week a 6.4% gain, which can change how you think about both potential and risk.
Recent coverage of ImmunityBio has focused on how its clinical pipeline and...